Menu
Search
|

Menu

Close
X

Reata Pharmaceuticals Inc RETA.OQ (NASDAQ Stock Exchange Global Market)

88.80 USD
+2.21 (+2.55%)
As of 5:30 PM BST
Previous Close 86.59
Open 85.61
Volume 19,960
3m Avg Volume 77,869
Today’s High 90.40
Today’s Low 85.61
52 Week High 104.34
52 Week Low 47.50
Shares Outstanding (mil) 26.10
Market Capitalization (mil) 832.70
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY19
16
FY18
54
FY17
48
FY16
50
EPS (USD)
FY19
-2.121
FY18
-2.859
FY17
-1.969
FY16
-0.289
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
16.46
7.91
Price to Book (MRQ)
vs sector
--
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
--
14.55
LT Debt to Equity (MRQ)
vs sector
--
10.20
Return on Investment (TTM)
vs sector
-63.77
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

J. Warren Huff
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $534,000.00
Bonus: $400,500.00
Manmeet Soni
Chief Financial Officer, Executive Vice President, Since 2019
Salary: --
Bonus: --
Dawn Bir
Executive Vice President, Chief Commercial Officer, Since 2018
Salary: --
Bonus: --
Colin Meyer
Chief Medical Officer and Executive Vice President, Product Development, Since 2018
Salary: $417,000.00
Bonus: $208,500.00
Jason Wilson
Executive Vice President - Operations, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2801 Gateway Dr Ste 150
IRVING   TX   75063

Phone: +1972.8652206

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

SPONSORED STORIES